The identification of myogenic precursor cells (mpc) is a key factor in determining the early events in the myogenesis and regeneration of skeletal muscle. Although satellite cells have long been established as the providers of myoblastic cells, very little is really known (apart from their anatomical location in relation to muscle fibres and their ability to migrate) about the precise role of satellite cells in myogenesis. Numerous techniques for labelling mpc have been devised, but none of these has proven to be completely reliable in firmly establishing the origin of myogenic cells. The use of tritiated thymidine to label DNA in proliferating mpc (which are not specifically distinguishable at the time) and the subsequent location of their labelled progeny in myotube nuclei has revealed a great deal of data on the timing of myogenesis, but not about the nature of mpc themselves. DNA synthesis can also be detected by antibodies to the thymidine analogue, bromodeoxyuridine, and also by antibody staining for proliferating nuclear cell antigen. Like tritiated thymidine, these other markers are not specific for muscle but are general markers for DNA synthesis. In situ hybridisation of various muscle-specific genetic markers and their products has been informative, as has immunolabelling of myogenin, MyoD1 and desmin. Desmin labelling has been particularly instructive in identifying mpc because it is one of the first muscle-specific proteins to be produced in mpc. This review covers some of the techniques mentioned above and their usefulness in determining the early events in myogenesis.

The identification of early, undifferentiated, myogenic precursor cells (mpc) has always been difficult and persists as one of the major problems in investigating the very earliest events in the myogenesis and regeneration of skeletal muscle. The fundamental problem relates to the fact that the most commonly acknowledged myogenic cell, the satellite cell, is quite undifferentiated and, apart from its anatomical position between the sarcolemma and the external lamina of the muscle fibre, it has no other distinguishing Correspondence to Professor John McGeachie, Department of Anatomy and Human Biology, The University of Western Australia, Nedlands, WA 6907 Australia. Tel : j61 8 9380 3301 ; fax : 61 8 9380 1051 ; e-mail : johnmcg!anhb.uwa.edu.au features. Also, following injury to muscle when satellite cells may move away from the damaged fibre, or migrate along its outer sarcolemmal membrane, satellite cells still have no distinguishable features. It is only when these cells (or those, possibly from still undetermined sources) start to express muscle-specific genes, or to produce muscle-specific proteins, that they can be identified as mpc. Thus much of the research on myogenesis over the last few years has concentrated on identifying such myogenic cell markers. However, some of the important works on myogenic cells have used nonspecific markers, such as tritiated thymidine ($H-TdR), to detect DNA synthesis in all cells associated with developing or regenerating tissues and to follow the labelled progeny of mpc in the later stages of myogenesis and muscle regeneration.
    

Tritiated thymidine ($H-TdR)
It has largely been through autoradiographic studies (Snow, 1977 (Snow, , 1978 Roberts et al. 1989 ; McGeachie & Grounds, 1990 ; Roberts & McGeachie, 1990 ) that mpc activity in regenerating skeletal muscle (after injury or transplantation) has been investigated. Autoradiographic techniques rely upon the uptake of radiolabelled isotopes, such as $H-TdR, by cells synthesising DNA in preparation for mitosis. With this methodology, all proliferating cells are labelled, rather than only myogenic cells and therefore replicating mononuclear cells located in the interstitial connective tissue (endothelial cells, fibroblasts, macrophages, etc.) cannot be distinguished from mononucleated undifferentiated mpc. Only by allowing sufficient time to elapse for the labelled mpc to differentiate into myoblasts and to fuse and form myotubes, can the progeny of the originally labelled mpc be identified (Roberts et al. 1989) . Therefore, by the subsequent analysis of labelled myotube nuclei, Fig. 1 . Diagrammatic representation of an experimental protocol for the injection of $H-TdR into mice at various times following muscle injury. All cells synthesising DNA at the time of injection incorporate the label. The progeny of mpc can be detected as autoradiographically labelled myotube nuclei later in the process of muscle regeneration (see Fig. 2 a) data can be gathered about the timing of mpc proliferative behaviour at the time of $H-TdR injection ; this is then related to the timing of the injury or insult (Figs 1, 2) .
Over the last decade this technique has revealed a substantial amount of data on the following aspects of myogenesis : the evidence against the hypothesis for the origin of ' circulating ' myoblasts from bone marrow (McGeachie & Grounds, 1985) ; reutilisation of $H-TdR in regenerating muscle (Grounds & McGeachie, 1987 a) ; the timing of mpc replication after muscle injury (Grounds & McGeachie, 1987 b, 1989 McGeachie & Grounds, 1987) ; mouse species differences in the timing and extent of mpc activity and regeneration (Grounds & McGeachie, 1989 b, 1990 Mitchell et al. 1992 ; McGeachie & Grounds, 1995) ; the influence of denervation on mpc activation (McGeachie & Grounds, 1989) ; effects of repeated injury on mpc activity (Morlet et al. 1989) ; myogenesis in dystrophic (mdx) muscle (Grounds & McGeachie, 1992 ; McGeachie et al. 1993) ; effects of growth factors and vasoactive substances on myogenesis (Mitchell et al. 1996 a, b) ; and the influence of age on mpc replication in different strains of mice (McGeachie & Grounds, 1995) . Moreover, there is a similar, equally substantial, body of data on the activity of mpc in experimental skeletal muscle grafts (summarised in Roberts & McGeachie, 1995) . Whilst these studies have revealed a great deal about the timing of mpc proliferation after injury or transplantation, they all suffer from the major drawback of not being able to identify mpc specifically. The injection of $H-TdR labels every cell in the body which is synthesising DNA at the time : it is quite nonspecific. This is why the muscle tissues must be left for some days for the mpc to become myoblasts and myotubes before a definitive identification of labelled myotube nuclei can be made. The other disadvantage of this technique is that $H-TdR will be diluted with each successive mitotic division and, over time, the signal may be so weak that it cannot be detected by autoradiography. Consequently this technique, whilst useful, is limited in its ability to identify mpc specifically. Therefore, what other techniques exist to overcome these problems ?
BrdU (5-bromo-2h-deoxyuridine) is an analogue of thymidine and it may be stained with antibodies to detect DNA synthesis in cells, including skeletal muscle. As with the use of $H-TdR, this technique is not specific for muscle and all cells synthesising DNA at the time of exposure to BrdU will stain positively for the antibody. One of the major advantages of BrdU is that it will reveal the cells which have incorporated it as soon as the antibody is applied, therefore it is often used on cell culture preparations where the proliferating cells are easily identified. This is a major advantage over the use of $H-TdR and autoradiography, where the preparations take many weeks to complete before the proliferating cells can be visualised. BrdU requires the use of frozen sections (to preserve the antibody binding sites), consequently the morphological detail achievable by this technique is not as good as with the use of $H-TdR, where high resolution microscopy can be used. Furthermore, $HTdR can be used to quantitate successive populations or generations of cells, by measuring the dilution of autoradiographic grains over labelled myotube nuclei (Grounds & McGeachie, 1987 b) . Such longer term analyses are very difficult with BrdU, because of the nature of the marker, which is detected by immunostaining or immunofluorescence. (This problem is further complicated by the ' toxic ' effect of BrdU on muscle cells ; see below.) However, BrdU has an added advantage in that it can be used in conjunction with other immunostains within the same muscle tissue for other skeletal muscle-specific markers. For example, the expression of the skeletal muscle-specific genes, MyoD and myogenin (see the section below on these genes), has been correlated with BrdU staining in the same muscle cells, to determine the intrinsic differences between the regenerative potential of 2 different strains of mice : BALB\c and SJL\J, in vitro (Maley et al. 1994) . Likewise, double staining techniques for BrdU and the muscle specific protein, desmin (see the section below), have revealed species differences (in vitro) in the coexpression of these 2 markers (Allen et al. 1991) . Also in vitro, the effect of the substrate, laminin, promoted myogenesis, as determined by double labelling for BrdU and desmin (Foster et al. 1987) . BrdU has been used in vivo to measure the contribution of cell proliferation during muscle hypertrophy in chickens (McCormick & Schultz, 1992) , and in developing fish muscle (Rowlerson et al. 1995) . It has also been used in vivo to determine the compensatory muscle growth during experimental limb lengthening procedures in rabbits (Day et al. 1997) , and myotube formation in rats (Zhang & McLennan, 1995) .
One concern with the use of BrdU is its toxicity to the labelled cells. Mostly it is used for short term experiments to determine the degree of proliferation occurring shortly after its introduction into the muscle system (in vitro or in vivo). This toxic effect has actually been used experimentally to inhibit differentiation of myoblasts into myotubes in vitro (Champaneria et al. 1989 ; Puliot et al. 1994 ; Blaschuk et al. 1997) . Therefore the use of BrdU needs to be carefully considered in relation to the hypothesis being tested and the length of time over which it is needed.
Proliferating cell nuclear antigen (PCNA)
Another method of detecting DNA synthesis in cells is to use an antibody to PCNA. PCNA is an auxiliary protein to polymerase delta and is expressed maximally in cells during S phase of the cell cycle (Tan et al. 1986 ; Bravo et al. 1987 ; Prelich et al. 1987 ; Baserga, 1991) . More specifically, PCNA can be used as a marker to determine the transition of a cell from the quiescent or resting phase (G ! ) into the DNA synthesis phase (S). PCNA is detected by the use of a specific antibody which is displayed by immunostaining or immunofluorescence. This marker has been used in studies on isolated skeletal muscle fibres from rats to determine the temporal expression of regulatory and structural proteins during myogenesis (Yablonka-Reuveni & Rivera, 1994) and also to study the proliferative dynamics and the role of fibroblast growth factor 2 (FGF2) during myogenesis (Yablonka-Reuveni & Rivera, 1997) . In vitro studies of muscle from rats of different ages have used PCNA to detect age-related differences in the proliferative responses of satellite cells (Johnson & Allen, 1993) . These studies show that cultured muscle cells accumulate PDNA prior to increases in cell numbers, and that the response was increased in young rats (3 wk) compared with old rats (9 mo). Moreover, basic FGF shortened the lag phase of PCNA synthesis in young rats but not in old rats (Johnson & Allen, 1993) . In a similar study in vitro, hepatocyte growth factor (HGF) was shown to activate quiescent skeletal muscle satellite cells : PCNA expression was accelerated under the influence of HGF, which indicated that satellite cells had entered the cell cycle earlier than in nontreated cells (Allen et al. 1995) . In otherwise terminally differentiated muscle cells in vitro, the influence of adenovirus E1A oncogene can reactivate the cell cycle (measured by PCNA expression) and suppress muscle-specific genes, MyoD and myogenin (Tiainen et al. 1996) .
In vivo, PCNA has been used to determine the timing of mpc proliferation in regenerating skeletal muscle and to correlate this with the differentiation of myoblasts by the detection of desmin production (Ono et al. 1993 ). This study showed that, as with the use of BrdU, double staining (for PCNA and desmin) can be used. Furthermore, the PCNA antibody data (Ono et al. 1993) show that the timing of mpc proliferation agrees very closely with those published from $H-TdR studies : the commencement of mpc proliferation is at about 24 h after injury and is maximal to 60-72 h (McGeachie & Grounds, 1987) . Also in vivo, satellite cell activation has been measured by PCNA in turkey muscle following denervation (Bakou et al. 1996) .
The advantages and disadvantages of PCNA compared with $H-TdR are very similar to those described above for BrdU and $H-TdR. The major advantage of PCNA over BrdU is that it does not have the toxic effect on myogenesis, as described above. These PCNA studies (as with the use of $HTdR or BrdU) are not specific for muscle cells : all these methods detect DNA synthesis in all proliferating cells. However, in combination with other skeletal muscle-specific markers for mpc and myogenesis, an enormous amount of information can be gathered on these important processes. The consideration of muscle-specific markers is the subject of the remainder of this paper.
      
To facilitate mpc identification, many studies have attempted to develop immunohistochemical markers (suitable for in situ hybridisation) which, unlike DNA labelling, are specific for quiescent or activated, but undifferentiated mpc. However, most of these markers have been ineffective ; either labelling nonmyogenic cells as well as mpc, or only labelling mpc in vitro and not in vivo. Antibodies recognising the surface adhesion molecule, NCAM, effectively label activated satellite cells in humans (Webster et al. 1988 ; Schaart et al. 1989) , rats and mice (Covault & Sanes, 1986) but are likely to be specific for cells located near neuromuscular junctions (Covault & Sanes, 1986) .
A potential mpc marker, the H36 antibody, developed by Kaufman & Foster (1988) , has been used (in conjunction with desmin) to label undifferentiated, replicating and differentiated mpc through its affinity for an integral membrane glycoprotein. The H36 antibody however, labels cultured rat mpc only and not mpc in vivo. Furthermore, it does not label mpc found within other species (Grounds, 1991) and hence it is not suitable for identifying mpc within regenerating mouse skeletal muscle. A different antibody, SAT2HIO, has been developed which labels mpc through its specificity for an antigen associated with actin filaments found within adult chicken mps (Yablonka-Reuveni, 1988) . The SAT2HIO antibody is considered unsuitable for labelling mpc in vivo because it also stains smooth muscle cells of the vasculature and other cells associated with capillary walls (Grounds & YablonkaReuveni, 1993) , and is only specific for mpc in vitro. Innovative techniques have been developed to identify presumptive satellite cells at the light microscopic level ; based on their (satellite) position between the external lamina and sarcolemma. Satellite cells have been either identified by antibodies to collagen IV and dystrophin respectively (Zhang & McLennan, 1994) , or within skeletal muscle fibres through the use of vital fluorescent dyes (Herrera & Banner, 1990) . However these methods are unsuitable for most studies because the satellite cell position can also be occupied by nonmyogenic cells, including macrophages (Trupin & Hsu, 1979) and pericytes (Venable & Lorenz, 1970) , and the mpc cannot be monitored once they move out of the satellite cell position, or once they start proliferating (Griffin et al. 1987) . In another study by Vater et al. (1994) , satellite cells, activated as part of the regeneration of skeletal muscle, were identified through the use of an antivimentin antibody (in conjunction with antilaminin antibody) through cryosectioning and Western blot labelling protocols. However, it appears that the vimentin labelling of satellite cells was subsequently lost with the time course of regeneration, and therefore vimentin labelling is really not suitable for investigating mpc.
MyoD and myogenin labelling
Initially it was thought that cardiac α-actin was the earliest muscle-specific gene expressed by mpc as part of the process of differentiation (Gunning et al. 1987) . However, the muscle-specific genes, myf-5 (Ott et al.
1991 ; Arnold & Braun, 1993) MyoD and myogenin, have since been shown in embryonic studies to be expressed by mpc at an even earlier stage of myogenesis, prior to differentiation (Hopwood et al. 1988 ; Scales et al. 1990 ; Sassoon, 1993) . MyoD and myogenin belong to a family of regulatory proteins in skeletal muscle which contain a helix-loop-helix motif. These also include Myf-3, Myf-4, Myf-5, Myf-6 and MRF-4. The genes for these regulate the expression of the skeletal muscle phenotype (Braun et al. 1989) .
MyoD is an abbreviation for ' Myoblast Determination ' gene, and it was one of the first of this family of myogenic genes to be identified (Davis et al. 1987 ; Weintraub et al. 1991) . Whilst this has now been identified as a muscle-specific gene, under selected conditions in vitro (as in its original discovery in 1987), it can cause nonmuscle cells, such as fibroblasts, to differentiate into muscle (Davis et al. 1987) . It is also expressed in ' myoid ' cells in the thymus (Grounds et al. 1992 a) . MyoD is a transcription factor in myogenesis and it has been suggested that its early expression (as detected by mRNA probes) did not signal the terminal differentiation of mpc, but that there was an interaction between the myogenic regulatory gene products and other helix-loop-helix proteins, such as to influence DNA binding during mpc proliferation (Grounds et al. 1992 b) .
Myogenin is also a member of the helix-loop-helix family and is a muscle regulatory gene acting as a transcription factor during myogenesis (Braun et al. 1989 ; Wright et al. 1989 ). It probably functions as a sequence specific DNA binding factor which interacts with other muscle-specific genes during myogenesis, in a similar fashion to MyoD (Wright et al. 1989 ). There are differences in the expression of MyoD and myogenin. MyoD (and myf-5) are expressed in several muscle cell lines in vitro prior to differentiation (Braun et al. 1989 ), whereas myogenin is expressed after the withdrawal of mitogens from myoblasts (Edmonson & Olson, 1989) . However, in embryonic somitic muscle, myogenin is expressed prior to MyoD or other muscle specific genes (Sassoon et al. 1993) .
In summary, the functions of MyoD and myogenin are very complex and they are definitely expressed very early in the myogenic cycle, within a few hours after muscle injury in vivo (Grounds et al. 1992 b) . Their functions are slightly different but they act as transcription factors to facilitate the expression of other muscle genes and the production of other muscle specific proteins. Data on the precise timing of these very early myogenic events differ according to whether the experiments were done in vitro (and according to which cell line was used) or in vivo. For further information the reader is referred to an informative review on the topic (Buckingham, 1994) . For the purposes of the present paper the development of specific markers for MyoD and myogenin have proved to be useful tools in identifying the earliest signs of myogenic determination, and these methods are described briefly below.
Techniques exist for labelling mpc based on the upregulation of the MyoD and myogenin genes and the expression of their respective proteins ; these have been used to detect mps within regenerating skeletal muscle. Myogenin-and MyoD-positive mps have been identified (in vitro) within primary cultures of skeletal muscle from BALB\c and SJL\J mice using in situ (riboprobes) and immunolabelling techniques (Maley et al. 1994 ). Furthermore, MyoD-positive proliferating cells have been detected within cultured rat myofibres and shown subsequently to become myogenin-positive (Yablonka-Reuveni & Rivera, 1994) . This effect has been reported as occurring within embryonic mouse skeletal muscle, both in vitro and in vivo, using immunolabelling (Cusella-De Angelis et al. 1992 ).
An immunohistochemical study, using MyoD and myogenin antibodies, reported that mpc within regenerating adult muscle could only be detected based on expression of these genes late in the myogenic cycle, immediately before fusion into myotubes (Fuchtbauer & Westphal, 1992) . However, Grounds et al. (1992 b) identified early mpc in situ in regenerating mouse muscle, using MyoD and myogenin riboprobes, within 6 h of being crush-injured. A more recent study by Rantanen et al. (1995) showed, by Northern blot hybridisation, increased amounts of myogenin mRNA as early as 4-8 h after (contusion and toxic) injury and detected myoD-and myogeninpositive mpc using immunolabelling 12 h after injury. Beilharz et al. (1992) also quantitated MyoD and myogenin expression using Northern Analysis (to monitor mRNA expression) in both adult regenerating muscle (following crush injury) and dystrophic mouse muscle of varying ages. The differences between the results of Fuchtbauer & Westphal (1992) , who studied transplanted minced muscle grafts, and these other studies which used a focal muscle injury model, may relate to differences in the timing of regeneration as a consequence of the different types of damage inflicted (Rantanen et al. 1995) . It has been shown that MyoD and myogenin are not expressed by satellite cells in normal uninjured adult muscle (Fuchtbauer & Westphal, 1992 ; Grounds et al. 1992 b) and rapid upregulation of these genes is now quite widely used to detect satellite cells as they become activated both in vitro (Smith et al. 1993 ) and in vivo (Koishi et al. 1995) . However, precisely when these genes are upregulated by mpc is not known.
Desmin
Expression. Desmin is a protein found in the intermediate filaments of the cytoskeleton of muscle cells (Lazarides & Hubbard, 1976) . Desmin is coded for by a single desmin gene (Li et al. 1989) , which is expressed by cells of smooth, cardiac and skeletal muscle (Lazarides & Hubbard, 1976) . In myogenesis, the desmin protein within undifferentiated mpc is expressed before myofibrillar proteins such as titin, skeletal muscle actin, myosin heavy chains and nebulin, which are expressed as part of differentiation (Hill et al. 1986 ). There is evidence that the onset of desmin expression (within myogenesis) and the extent of desmin expression may differ between species, as Allen et al. (1991) reported that demin is expressed in vitro by rat mpc but not by bovine mpc.
Distribution. In mononuclear mpc, prior to myotube formation, desmin protein is randomly and radially expressed. However, following the fusion of myoblasts, desmin accumulates and becomes more organised (Kaufman & Foster, 1988 ; Li & Paulin, 1991) . Within mature skeletal muscle, intermediate filaments stain desmin-positive (following incubation with the antidesmin antibody) along the transverse bands surrounding the Z lines (disks) and connecting myofibrils (Lazarides & Hubbard, 1976 ; Helliwell, 1988 ; Kaufman & Foster, 1988 ; Borneman & Schmalbruch, 1992) .
Function. The precise function of the desmin protein in mpc or in mature muscle is unknown (Li et al. 1994) , as indeed is the biological role of intermediate filaments to which desmin contributes (Klymkowsky et al. 1989 ). Based on evidence from a number of studies there are several plausible roles for the desmin protein. As the main component of intermediate filaments in neonatal and adult muscle (Lazarides, 1980) , desmin may be involved in the maintenance of the organisation of myofibres (Gard & Lazarides, 1980) and establishing the lateral registry of sarcomeres (Brocks et al. 1991 ). In addition, Lie et al. (1994) have shown that inhibition of the desmin gene inhibits the terminal stages of myogenesis, involving mpc fusion and formation of muscle fibres. On account of the evidence that desmin interconnects the nucleus with the plasma membrane (Granger & Lazarides, 1979 ; Li et al. 1994 ) it suggests that desmin may regulate myogenesis via the nucleus through the myogenic regulators responsible for terminal differentiation. Furthermore, Vater et al. (1992) , having observed changes in desmin and another intermediate filament protein, titin, during the necrosis and regeneration of an injured soleus muscle, hypothesised that desmin may be involved in establishing and maintaining the structural integrity of muscle fibres. Clearly, there are numerous plausible roles for this intermediate filament protein, desmin, in skeletal muscle cells. Thus the possibility exists for using desmin as a marker for mpc and myoblasts in studies of myogenesis and regenerating muscle.
Desmin labelling. Originally desmin was thought to be synthesised only by terminally differentiated myoblasts (Holtzer et al. 1972 ; Gard & Lazarides, 1980) ; however, desmin has since (along with MyoD and myogenin) been shown to be one of the earliest genes expressed by undifferentiated mpc, as part of both embryonic and adult myogenesis (Kaufman & Foster, 1988 ; Furst et al. 1989 ; Schaart et al. 1989 ; Sassoon, 1993) . (Fig. 3 shows myogenic cells stained for desmin.)
In studies performed on skeletal muscle in vitro, immunohistochemical methods have been used to label mpc expressing desmin. Desmin is expressing in proliferating mpc from embryonic and adult rats in culture (Foster et al. 1987 ; Allen et al. 1991) . It is also detected in proliferating mpc from young chick embryos (Hill et al. 1986 ; Yablonka-Reuveni & Nameroff 1986 , 1990 Li et al. 1994) , and in cultured adult human muscle (van der Ven et al. 1992 ; Behr et al. 1994) . Further studies have identified mpc based on desmin expression even prior to undergoing replication. In studies performed on cultured neonatal rat muscle, desmin-positive quiescent and activated satellite cells have been detected (Kaufman & Foster, 1988 ; Zhang & McLennan, 1994) , as evidence of the usefulness of desmin markers to detect very early mpc. In another study, mpc were detected expressing desmin (using both in situ and immunohistochemical techniques) in SJL\J and BALB\c mouse muscle cultures before MyoD and myogenin mRNA were detected (Maley et al. 1994) . These studies all point to desmin as a very useful marker to detect early activated mpc in vivo.
Following an injury to skeletal muscle in vivo, mpc become desmin-positive at a very early time within the myogenic cycle : this is further evidence of mpc being identified on the basis of desmin expression (Roberts et al. 1997) . Desmin-positive proliferating cells have been observed in regenerating rat skeletal muscle (Helliwell, 1988 ; Allen et al. 1991) and regenerating dystrophic murine muscle (Brocks et al. 1991) . Mpc have been shown to express desmin in adult rat muscle as early as 12 h after injury (Rantanen et al. 1995) , suggesting that both in vivo and in vitro desmin labelling techniques can be used to identify mpc very soon after injury.
       
Techniques that detect the expression of MyoD, myogenin, and desmin genes within mpc could all be used to label activated mpc in regenerating skeletal muscle. Within our research group, MyoD and myogenin-positive mpc have been detected in vitro and in vivo, using Northern analysis and MyoD and myogenin-specific probes (Beilharz et al. 1992 ; Grounds et al. 1992 b) . Furthermore, by the use of immunohistochemical techniques, myogenin and desmin-positive mpc have been detected in vitro (Maley et al. 1994) . As an alternative to immunohistochemical techniques, transgenic mice which have had a lacZ construct (which expresses β galactosidase, when upregulated) added to their desmin gene to form a desmin transgene, could be used to identify mpc expressing desmin (Li et al. 1993) . Following injury, as mpc become activated and upregulate the desmin lacZ transgene, they become β galactosidase-positive and hence may be easily identified by staining.
Immunohistochemical labelling is a simpler and a more convenient technique than in situ hybridisation. It is well established that the antidesmin antibody successfully labels mpc within regenerating skeletal muscle in vivo. However, in addition to mpc, vascular smooth muscle and the edge of mature muscle fibres (containing the desmin protein) stain desmin-positive, and this can complicate the identification of mpc in skeletal muscle regenerating after crush or other injury (Grounds, 1991 ; Grounds & YablonkaReuveni, 1993 ; Zhang & McLennan, 1994) . However, when investigating mpc within transplanted whole muscle grafts, these difficulties are avoided because the onset of revascularisation is not initiated until 3 d after transplant insertion and this is the time that myogenesis is detectable by using DNA labelling (Roberts & McGeachie, 1992) . Furthermore, the antidesmin antibody intensely stains the cytoplasm (surrounding the nucleus) of mpc in such a manner that they can be easily distinguished from staining at the edges of intact\surviving myofibres.

Presently there is a range of techniques to label mpc in developing and regenerating skeletal muscle. Some of the data published show that myogenic cells which are expressing muscle-specific genes, can be identified in regenerating muscle with 6 h after injury. The challenge ahead for muscle biologists is to refine techniques for the early identification of mpc so that the precise temporal sequence of gene expression and protein synthesis can be elucidated. These revelations will go a long way to unravelling the details of skeletal muscle myogenesis, a process which is vital to understand in relation to the embryogenic histogenesis of muscle, its regeneration after injury and the pathological processes involved in muscular dystrophies. 
